Dynavax Technologies Corporation
Dynavax Technologies Corporation (DVAX) Revenue
Annual & quarterly revenue history · segment & region breakdown
DVAX · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsDynavax Technologies Corporation trailing twelve-month (TTM) revenue is $0.33B, an increase of 19.36% year-over-year from $0.28B in FY2024.
Revenue trend
2024 – 2005 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2024-12-31 | $0.28B | +$0.04B | +19.36% |
| 2023-12-31 | $0.23B | -$0.49B | -67.86% |
| 2022-12-31 | $0.72B | +$0.28B | +64.45% |
| 2021-12-31 | $0.44B | +$0.39B | +844.00% |
| 2020-12-31 | $0.05B | +$0.01B | +32.18% |
| 2019-12-31 | $0.04B | +$0.03B | +329.60% |
| 2018-12-31 | $0.01B | +$0.01B | +2407.03% |
| 2017-12-31 | $0.00B | -$0.01B | -97.04% |
| 2016-12-31 | $0.01B | +$0.01B | +172.67% |
| 2015-12-31 | $0.00B | -$0.01B | -63.29% |
Compare revenue vs peers
Drug Manufacturers - Specialty & GenericCompare DVAX revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Dynavax Technologies Corporation receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Dynavax Technologies Corporation reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Dynavax Technologies Corporation's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
DVAX revenue · 4 questionsDVAX's trailing twelve-month (TTM) revenue is $0.33B. That is an increase of 19.36% year-over-year from $0.28B in FY2024.
▸ Source: FMP · Dynavax Technologies Corporation SEC filings · GAAP · Dynavax Technologies Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026